Introduction {#s1}
============

Nuclear factor-kappa B (NF-kB) is a transcription factor that plays a major role in various biological processes including the immune system development, activation, and regulation. This transcription factor complex is held inactive in the cytoplasm by the inhibitor of NF-kB (IκB). The classical activation pathway of NF-kB is triggered by a large number of extracellular stimuli through different receptors, which result in the phosphorylation of IκB by IκB kinase (IKK complex; IKKα, IKKβ/IKK2, and IKKγ/NEMO) and the subsequent release of NF-kB complex so it can translocate into the nucleus and drive target gene expression ([@B1]).

Different primary immunodeficiency disorders result from genetic defects that involve components linked to the NF-kB activation pathway ([@B2]). IKK2 deficiency is a recently described combined immunodeficiency disease that leads to impairment of NF-kB signaling ([@B3]). Affected patients develop early severe and recurrent infections caused by bacterial, viral, fungal, and mycobacterial organisms. Unlike patients with IKKα and IKKγ mutations, IKK2-deficient patients do not typically have ectodermal dysplasia. Indeed, out of 22 patients with IKK2 deficiency described in the literature, only one patient has ectodermal dysplasia in the form of conical teeth ([@B3]--[@B7]).

Herein, we describe the clinical manifestations and the immunologic features of four Saudi patients from two related families with a diagnosis of combined immunodeficiency due to novel homozygous non-sense mutation in *IKBKB*.

Methods {#s2}
=======

The medical records of four Saudi patients from two related families with a diagnosis of combined immunodeficiency were reviewed. The clinical and immunological data were collected. Autozygosity mapping of all available members and whole exome sequencing of the index member were performed as previously described ([@B8]). Written consent was obtained from the parents. The study was approved by the Research Advisory Council at King Faisal Specialist Hospital and Research Center (RAC\# 2121053).

Results {#s3}
=======

Our patients (V:1, V:2, V:5, and V:8) belong to two related Saudi families ([Figure 1A](#F1){ref-type="fig"}). They had early onset (2--4 months of age) severe infections caused by viruses, bacteria, mycobacteria, and fungi. The organisms include *Klebsiella pneumonuia, Candida albicans*, CMV, and BCG ([Table 1](#T1){ref-type="table"}), which were associated with different clinical manifestations ([Table 1](#T1){ref-type="table"}). Interestingly, all four patients had delayed umbilical cord separation at 2 months. They all displayed hypogammaglobulinemia. Where data is available, they had low absolute lymphocyte count (420--2,680 cells/mm^3^), and their lymphocytes failed to respond to PHA mitogen ([Table 1](#T1){ref-type="table"}). A novel homozygous non-sense mutation in the *IKBKB* gene, c.850C\>T (p. Arg284\*) ([Figures 1B,C](#F1){ref-type="fig"}) was identified in patient V:5 within the candidate autozygome, and Sanger sequencing confirmed its segregation with the disease in the remaining living siblings and parents ([Figures 1A,B](#F1){ref-type="fig"}). Three patients (V:1, V:2, and V:8) succumbed to their disease\'s infectious complications before commencing hematopoietic stem cell transplantation (HSCT).

![**(A)** Pedigree of study family. ± represent segregation status of different individuals. **(B)** Segregation of NM_001190720: c.850C\>T mutation in parents and recruited unaffected siblings. **(C)** Cartoons for IKBKB transcript and protein domains; arrows point to the position of mutated base. I in last protein\'s domain stand for I-kappa-kinase-beta NEMO binding domain. \*Indicates nonsense mutation resulting in termination of translation (truncated protein).](fped-08-00009-g0001){#F1}

###### 

The clinical and immunological characterization.

                                             **V:1**                                                             **V:2**                                                                                      **V:5**                                     **V:8**
  ------------------------------------------ ------------------------------------------------------------------- -------------------------------------------------------------------------------------------- ------------------------------------------- -----------------------------------------------
  Cord separation                            2 months                                                            2 months                                                                                     2 months                                    2 months
  Onset                                      4 months                                                            3 months                                                                                     3 months                                    2 months
  Infections                                 Disseminated BCGitis                                                Perinatal CMV, *Klebsiella pneumoniae* sepsis, UTI, and pneumonia                            Oral candidiasis and Disseminated BCGitis   *Klebsiella pneumoniae* sepsis and meningitis
  Others                                     Extensive Maculopapular skin rash Pancytopenia Hepatosplenomegaly   Intracranial calcification Chorioretinitis Microcephaly Axial hypotonia Hepatosplenomegaly   Hepatosplenomegaly Maculopapular rash       
  IgG[^\*^](#TN1){ref-type="table-fn"}       0.75 g/L                                                            1.39 g/L                                                                                     0.574 g/L                                   2.679 g/L
  IgM[^\*^](#TN1){ref-type="table-fn"}       0.56 g/L                                                            0.26 g/L                                                                                     Undetectable                                0.268 g/L
  IgA[^\*^](#TN1){ref-type="table-fn"}       Undetectable                                                        Undetectable                                                                                 Undetectable                                0.425 g/L
  IgE[^\*^](#TN1){ref-type="table-fn"}       NA                                                                  Undetectable                                                                                 Undetectable                                NA
  WBC                                        NA                                                                  NA                                                                                           8,300/mm^3^                                 NA
  ANC                                        NA                                                                  NA                                                                                           5,890/mm^3^                                 NA
  ALC[^\*^](#TN1){ref-type="table-fn"}       420/mm^3^                                                           2,680/mm^3^                                                                                  1,030/mm^3^                                 NA
  CD3[^\*^](#TN1){ref-type="table-fn"}       260/mm^3^                                                           NA                                                                                           665/mm^3^ (65%)                             NA
  CD4[^\*^](#TN1){ref-type="table-fn"}       210/mm^3^                                                           NA                                                                                           493/mm^3^ (48%)                             NA
  CD8[^\*^](#TN1){ref-type="table-fn"}       50/mm^3^                                                            NA                                                                                           126/mm^3^ (12%)                             NA
  CD19[^\*^](#TN1){ref-type="table-fn"}      50/mm^3^                                                            NA                                                                                           264/mm^3^ (26%)                             NA
  CD16/56[^\*^](#TN1){ref-type="table-fn"}   100/mm^3^                                                           NA                                                                                           68/mm^3^ (7%)                               NA
  PHA[^\*^](#TN1){ref-type="table-fn"}       RR%: 8%                                                             RR%: 15%                                                                                     RR%: 20%                                    NA
  Outcome                                    Died at 6 months                                                    Died at 8 months                                                                             Transplanted                                Died at 3 months

*Normal range for age: at 3 months: IgG (1.76--5.81 g/L), IgM (0.24--0.89 g/L), IgA (0.046--0.46 g/L), IgE (0.18--3.76 IU/ml). At 6 months: IgG (2.15--7.04 g/L), IgM (0.35--1.02 g/L), IgA (0.081--0.68 g/L), IgE (0.44--16.3 IU/ml). Absolute lymphocyte count (ALC): 4,054--7,048 cells/mm~3~, CD3: 3,100--4,800 cells/mm^3^ (61--70%), CD4: 2,200--3,300 cells/mm^3^ (38--51%), CD8: 1,100--1,700 cells/mm^3^ (18--27%), CD19: 1,100--1,900 cell/mm^3^ (20--27%), CD16/56: 300--700 cells/mm^3^ (5--11%), PHA (phytohemoagglutinin) RR%: 75--100%. RR, the ratio of the patient response to the mean of two normal control responses*.

Patient V:5 underwent HSCT from a fully matched sibling (10/10) at 19 months of age. To save his life and because of the disseminated BCGitis, he received no conditioning and no GVHD prophylaxis. The CD34 dose was 9.2 × 10^6^/kg. He had persistent lymphoid engraftment ranging from 7 to 40% (2 weeks to 2.5 years after HSCT) but no myeloid engraftment. He developed acute gut graft-vs.-host disease (GVHD) 2 months after HSCT that responded to cyclosporine A and steroid treatment. Six months later, he developed chronic gut GVHD that was controlled by the same medications. Although his lymphocyte subsets \[CD3 2,409/mm^3^ (79%), CD4 1,211/mm^3^ (40%), CD8 1,183/mm^3^ (39%), CD19 296/mm^3^ (10%), CD16/56 307/mm^3^ (10%)\] and their proliferation response to PHA (relative ratio 127%) showed good recovery, clinically, he did not show good immune reconstitution. He continued to suffer from disseminated BCGitis with bony involvement requiring frequent surgical interventions for faciozygomatic osteomyelitis. More than 4 years after the transplant, he was still on anti-mycobacterial medications (cycloserine, clarithromycin, ethambutol, and levofloxacin), monthly IVIG, and pentamidine prophylaxis. The last chimerism test was done at 4.5 years post-transplantation and showed 23% lymphoid engraftment and no myeloid engraftment. The severe disseminated BCGitis and history of GVHD precluded another trial of transplantation.

Discussion {#s4}
==========

This is the largest cohort of IKK2 deficiency reported in the Saudi population. In general, the clinical features of our patients were not different from previously reported cases. Susceptibility to a wide range of infections caused by opportunistic and non-opportunistic organisms were commonality. The generalized maculopapular rash, hepatosplenomegaly, chorioretinitis, and CNS complications in our patients are probably related to the chronic CMV and disseminated BCG infections. All reported patients succumbed to their disease during infancy unless they had successful HSCT ([Table 2](#T2){ref-type="table"}). On average, the degree of lymphopenia was more profound in our patients (420--2,680/mm^3^) compared to others (1,520--11,850/mm^3^) ([@B7]). Interestingly, all our patients had delayed umbilical cord separation \[normal separation occurs in 1--2 weeks ([@B8])\] Patient V:6, who died in infancy from a febrile illness before diagnosis and the identification of the genetic defect in the family, was also reported to have had delayed separation of the umbilical cord. None of the reported patients with IKK2 deficiency had delayed cord separation except one from Saudi Arabia, but with a different mutation ([@B3]--[@B7]). No neutrophil chemotaxis or adhesion assay was done for the patients. Delayed cord separation was reported in conditions that affect neutrophil number and/or compromise their function including leukocyte adhesion defects as well as MyD88 and IRAK4 deficiency, which are upstream to the NF-κB activation pathway ([@B9]--[@B12]). This feature may be a clue to IKK2 deficiency in patients with combined immunodeficiency. The mechanism by which *IKBKB* mutation may predispose to delayed cord separation is not clear. It has been reported that neutrophil infiltration was prominent during the cord separation process in healthy babies, and a defect in neutrophil chemotaxis and adhesion was illustrated in cases of leukocyte adhesion deficiency ([@B13]). Since all IKK2 deficiency patients in the literature did not exhibit delayed cord separation except one Saudi patient with a different mutation, it is likely that this feature is a result of a complex interaction between the *IKBKB* defect and other modifier genes.

###### 

Summary of patients with IKK2 deficiency previously reported in the literature.

  **Patient (references)**   **Onset**                     **Clinical manifestation**                                                                                                                                                                                                                                           **HSCT**   **Age at 1st/2nd HSCT**   **Donor**              **HLA match**                    **Conditioning**   **GVHD prophylaxis**      **Outcome/cause of death**                           **Age at death**
  -------------------------- ----------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------- ------------------------- ---------------------- -------------------------------- ------------------ ------------------------- ---------------------------------------------------- ---------------------
  P1 ([@B7])                 Unknown                       Disseminated BCGitis                                                                                                                                                                                                                                                 No         NA                        NA                     NA                               NA                 NA                        Died/infection                                       \<4 months
  P2 ([@B7])                 3 months                      Bacteremia, otitis media, pyelonephritis, pneumonia, tinea capitis, and oropharyngeal and perineal candidiasis. Causative organisms: *Klebsiella pneumoniae, E. coli* and polymicrobial gram negatives                                                               No         NA                        NA                     NA                               NA                 NA                        Died/infection                                       14 months
  P3 ([@B7])                 2 weeks                       Recurrent bacteremia, recurrent pneumonia, oral thrush, and disseminated HSV. Causative organisms are *E. coli*                                                                                                                                                      Yes        19 months                 Father                 6/6                              MAC                None                      Died/not reported                                    7 years
  P4 ([@B7])                 2.5 months                    Disseminated BCGitis, disseminated CMV, disseminated adenovirus, bacteremia. Causative organisms: *Streptococcus pneumoniae, Stenotrophomonas maltophilia*                                                                                                           Yes        4 months                  Half-sibling           10/10                            None               None                      Died/not reported                                    4 months
  P5 ([@B7])                 1 month                       Disseminated BCGitis, disseminated CMV, candidal meningitis, oral thrush, varicella zoster infection, and bacteremia. Causative organisms: *E. coli, Morganella morganni, Staphylococcus aureus*                                                                     No         NA                        NA                     NA                               NA                 NA                        Died/infection                                       5 months
  P6 ([@B7])                 3.5 months                    Disseminated adenovirus, disseminated CMV, oral thrush, and bacteremia. Causative organisms: *E. coli, Pseudomonas aeroginosa*                                                                                                                                       Yes        4.5 months/not recorded   Mother/mother          10/10                            None/MAC           Tacrolimus/methotrexate   Died/not reported                                    8 months
  P7 ([@B7])                 2 months                      *Listeria monocytogenes* bacteremia and meningitis and oral thrush                                                                                                                                                                                                   No         NA                        NA                     NA                               NA                 NA                        Died/infection                                       2 months
  P8 ([@B7])                 1 month                       Oral thrush, pneumonia and bacteremia. Causative organism: *E. coli*                                                                                                                                                                                                 Yes        5 months                  Unrelated              6/6                              RIC                Tacrolimus/methotrexate   Died/not reported                                    2 years
  P9 ([@B7])                 1 month                       Oral and perineal candidiasis, RSV pneumonia, bacteremia and meningitis. Causative organisms: *Staphylococcus aureus, Enterococcus fecalis, Enterococcus faecium*, and *Leuconostoc lactic*                                                                          No         NA                        NA                     NA                               NA                 NA                        Died/infection                                       15 months
  P10 ([@B7])                3 months                      Oral thrush, bacteremia, and pneumonia. Causative organisms: Parainfluenza, *Mycoplasma pneumoniae, Staphylococcus hominis*, and *Enterococcus faecium*                                                                                                              Yes        7 months                  Brother                10/10                            MAC                Tacrolimus/methotrexate   Alive 7 years                                        NA
  P11 ([@B7])                2 months                      Oral thrush, scabies, pneumonia, and meningitis. Causative organisms: rhinovirus and *Klebsiella pneumoniae*                                                                                                                                                         No         NA                        NA                     NA                               NA                 NA                        Died/infection                                       2.5 months
  P12 ([@B7])                3 months                      Oral thrush, candidal UTI, bacteremia and brain abscesses, and pneumonia. Causative organisms: *Serratia marcescens, E. coli, Klebsiella pneumoniae*, RSV, coronavirus. Hemophagocytic lymphohistiocytosis                                                           Yes        8 months                  Unrelated              5/6                              MAC                Tacrolimus/methotrexate   Alive 6 years                                        NA
  P13 ([@B7])                4 months                      Sepsis                                                                                                                                                                                                                                                               No         NA                        NA                     NA                               NA                 NA                        Died/infection                                       2.5 months
  P14 ([@B7])                2.5 months                    Disseminated BCGitis, candidemia, and bacteremia. Causative organisms: *E. coli, Stenotrophomonas maltophilia, Enterobacter cloacae*                                                                                                                                 No         NA                        NA                     NA                               NA                 NA                        Died/infection                                       3.5 months
  P15 ([@B7])                Newborn (newborn screening)   None                                                                                                                                                                                                                                                                 Yes        2 months                  Unrelated              5/6                              MAC                Tacrolimus/methotrexate   Died                                                 11 months
  P16 ([@B7])                Newborn (family history)      None                                                                                                                                                                                                                                                                 Yes        1 month                   Unrelated              5/6                              MAC                Tacrolimus/methotrexate   Alive 6 months                                       NA
  P17 ([@B5])                5 months                      *Pneumocytis jirovecii pneumonia*, disseminated BCGitis                                                                                                                                                                                                              No         NA                        NA                     NA                               NA                 NA                        Died/BCGitis and cardiac arrest                      14 months
  P18 ([@B4])                2 months                      Omphalitis, delayed separation of the umbilical cord, *Salmonella* sepsis, disseminated BCGitis, recurrent infections. Causative organisms: *Acinetobacter, Enterobacter, Stenotrophomonas*, and *Achromobacter* species, rotavirus, and *Candida*. Conical teeth.   No         NA                        NA                     NA                               NA                 NA                        Died/massive bleeding after central line insertion   25 months
  P19 ([@B6])                5 months                      *Candida*, BCGitis                                                                                                                                                                                                                                                   Yes        Not recorded              Father                 identical                        MAC                Not recorded              Alive                                                
  P20 ([@B6])                11 months                     *Candida*, BCGitis, rota virus                                                                                                                                                                                                                                       Yes        Not recorded              Unrelated Cord blood   Not recorded                     MAC                Not recorded              Died/infection                                       2 months post HSCT
  P21 ([@B6])                7 months                      *Candida*                                                                                                                                                                                                                                                            Yes        Not recorded              Father                 T-cell depleted haploidentical   MAC                Not recorded              Died/infection                                       1 year post HSCT
  P22 ([@B6])                6 months                      *Candida, Klebsiella*, CMV                                                                                                                                                                                                                                           Yes        Not recorded              Mother                 T-cell depleted haploidentical   MAC                Not recorded              Died/infection                                       13 months post HSCT

*MAC, myeloablative conditioning; RIC, reduced intensity conditioning; NA, not available*.

On the other hand, a gain-of-function (GOF) mutation in *IKBKB* leads to a relatively mild form of combined immunodeficiency, ectodermal dysplasia, and immune dysregulation, where affected patients may live to their fourth decade. Although both diseases result in hypogammaglobulinemia and lymphopenia, patients with *IKBKB* GOF mutation have lower number of naïve T lymphocytes with overactivated memory cells ([@B14]).

In our index patient, his unstable clinical condition and the disseminated BCGitis dictated the decision of non-conditioned HSCT. The fact that he had a sustained lymphoid engraftment without conditioning is likely due to the severe T-cell dysfunction in this type of immunodeficiency. We do not have a clear explanation why our index case did not clear the disseminated BCGitis inspite of the recovered *in vitro* lymphoproliferative response to PHA. One possibility is that the donor cells are anergic to BCG, but we could not test for that. So far, 13 out of 27 patients with IKK2 deficiency including our cohort had undergone HSCT. Only five were alive at the time of reporting, while those who did not receive HSCT succumbed to their disease in their infancy or early childhood. All survivors received myeloablative conditioning except our patient, while the remaining eight patients received non-myeloablative conditioning (*n* = 5), reduced intensity conditioning (*n* = 1), or no conditioning (*n* = 2) ([@B14]). Although it is difficult to draw a conclusion from such limited number of reported patients, it seems that no conditioning or reduced intensity conditioning are not sufficient to cure the disease, and myeloablative protocol is needed to establish a good immune reconstitution.
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